anti-respiratory syncytial virus monoclonal antibodies (Mapp Biopharmaceutical/Baylor College of Medicine)

N/A

Report date: 2025/03/18 18:06:13

Base Information

Drug Nameanti-respiratory syncytial virus monoclonal antibodies (Mapp Biopharmaceutical/Baylor College of Medicine)
Drug Alias Nameanti-respiratory syncytial virus monoclonal antibodies (Mapp Biopharmaceutical/Vanderbilt University)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMapp Biopharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesMapp Biopharmaceutical Inc
Inactive CompaniesBaylor College Of MedicineVanderbilt University
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A